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angiogenesis but promotes somewhat less inflammation and vascular hyperpermeability than VEGF. 6 However, VEGF-E is potentially immunogenic because of its virus-derived epitopes; the same concern applies to molecules comprising parts of VEGF-E and placenta growth factor. 7 VEGF-B hardly stimulates new vessel formation in skeletal muscle, but recent studies have shown that its high or prolonged overexpression leads to an impressive expansion of the coronary vasculature. 8 Recent studies have also indicated that the lymphangiogenic growth factors VEGF-C and VEGF-D induce functional blood and lymphatic vessels in mouse and rabbit skeletal muscle, but this effect was accompanied by infiltration of inflammatory cells. 9, 10 A chimeric protein comprising the receptor-binding VEGF homology domain of VEGF, flanked by VEGF-C-derived Nand C-terminal propeptides, 11 induced less vessel permeability but retained the property of inflammatory cell recruitment. 10 Interestingly, 1 of the 2 naturally occurring VEGF-D isoforms, generated by alternative proteolysis (D ), was recently shown to be a specific VEGFR-2 ligand that was weakly angiogenic without evidence of lymphangiogenic activity. 12 Thus, the search is still ongoing for efficient vascular growth factors without permeability and inflammatory properties. Angiopoietin-1 (Ang1) signaling has been shown to mediate vessel stabilization and to inhibit vascular leak induced by a variety of stimuli. 13 Ang1 also inhibited VEGF-induced leukocyte adhesion to endothelial cells. 14 Coexpression of VEGF and Ang1 in the skin of transgenic mice resulted in the generation of larger, leakage-resistant vessels. 15 In subsequent studies, attempts were made to overexpress Ang1 with VEGF in a therapeutic setting, delivered via the same or separate viral vectors. 16, 17 In these studies, Ang1 was shown to recruit pericytes and smooth muscle cells, facilitating the formation of more mature vessels, which were less leaky for plasma proteins.
To combine the desired growth factor properties into a single protein, we have designed a chimeric molecule by fusing the receptor-binding parts of human VEGF and Ang1. We show that the angiogenic activity of this molecule is similar to that of VEGF, but it induces many fewer vessel abnormalities and much less leakiness and tissue inflammation than VEGF.
Methods
Tissue Transduction With the Recombinant Adeno-Associated Viral Vectors
Six-to 7-week-old female FVB/N mice were anesthetized with xylazine (Rompun Vet; Bayer Healthcare, Leverkusen, Germany) and ketamine (Ketalar; Pfizer, New York, NY), and 3×10 10 recombinant adeno-associated viral (rAAV) particles (in 30-µL volume) were injected into each tibialis anterior muscle. All mouse experiments were approved by the Provincial State Office of Southern Finland and were carried out in accordance with institutional guidelines.
Immunohistochemistry of Skeletal Muscle Samples
The tibialis anterior muscles were isolated and frozen in OCT (optimal cutting temperature). Cryosections (10 μm) were cut, fixed in acetone, and immunostained with rat anti-platelet endothelial cell adhesion molecule-1 (BD Biosciences), rat anti-CD45 (BD Biosciences), rat F4/80 (AbD Serotec; MorphoSys AG), mouse anti--smooth muscle actin--Cy3 (Sigma-Aldrich), rat anti-mouse NG2, or goat anti-mouse platelet-derived growth factor receptor-β (R&D Systems). Hoechst 33258 was used for DNA staining. The microvessel area density was quantified with ImageJ software (National Institutes of Health).
Results are presented as mean±SD. The samples were analyzed with either an Axioplan 2 microscope (Carl Zeiss AG; objectives, ×10 numerical aperture (NA)=0.3 working distance (WD) 5.6 mm and ×20 NA=0.5 and WD 2.0 mm; camera, Zeiss AxioCamHRm 14-bit grayscale charge-coupled device; acquisition software, Zeiss AxioVision 4.6) or an LSM 510 Meta confocal microscope equipped with a digital camera (Carl Zeiss AG; objective, ×10 Fluar 0.50, Differential Interference Contrast (DIC); acquisition software, LSM release 3.2).
Fluorescent Angiography of Blood Vessels via Cardiac Perfusion
Blood vessels were directly visualized by cardiac perfusion with the lipophilic carbocyanine dye 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate (DiI) as described previously. 10 After perfusion, the tibialis anterior muscle was isolated, and 120-μm sections were analyzed by confocal microscopy using an excitation wavelength of 543 nm.
Miles Assay in Skeletal Muscle
rAAVs encoding VA1, VEGF, Ang1, Ang2, or human serum albumin were expressed for 2 weeks in the tibialis anterior muscles of 2-monthold FVB/N female mice. The mice were anesthetized, and 300 µL of 1% Evans Blue (in PBS) was injected into the tail vein. The dye was allowed to circulate for 30 to 45 minutes, followed by cardiac perfusion with PBS (10 mL per mouse). Tibialis anterior muscles were isolated and weighed, and the dye was extracted overnight with deionized formamide (1 mL per muscle) and measured at an optical density of 620 nm.
In Vivo Signal Transduction Studies
FVB/N mice were injected intravenously via the tail vein with pure proteins at the doses indicated in the figure legends and in the text. Mice were euthanized by cervical dislocation after various periods of time (10, 30, or 60 minutes). Lungs were flash-frozen in liquid nitrogen and stored until use. Tissue samples were homogenized in lysis buffer (0.5% Triton X-100/0.5% NP-40 in PBS supplemented with protease and phosphatase inhibitors using PowerLyzer 24 Bench Top Bead-Based Homogenizer, MO BIO Laboratories, Inc); insoluble material was removed by centrifugation in a bench-top centrifuge (200 00g at 4ºC for 5 minutes); and protein concentration was determined by the Bradford method. Soluble protein (200 µg) was resolved in 4% to 20% SDS-PAGE, transferred onto polyvinylidene difluoride membrane, and Western blotted with the indicated antibodies.
Statistical Analysis
If equal variances were assumed, we evaluated statistical significance by 1-way ANOVA followed by the Dunnett (2-sided) post hoc test, with values of P<0.05 regarded as significant. When pairwise comparisons between experimental groups were made, the Tukey test was used. If the variances were not equal, the Games-Howell test was used as a post hoc test, with values of P<0.05 regarded as significant. When appropriate, an unpaired t test was also used. The results are presented as mean±SD unless indicated otherwise.
An expanded Materials and Methods section containing detailed descriptions of the construction, production, and testing of the rAAV vectors; cell survival assay using methylthiazolyldiphenyltetrazolium bromide (MTT, Sigma-Aldrich); protein expression and purification; quantification of growth factor expression in transduced skeletal muscle by ELISA; immunocytochemistry; biotinylation and ubiquitinylation experiments; immunohistochemistry; Doppler ultrasound measurement of blood perfusion; and hind-limb ischemia models is provided in the online-only Data Supplement.
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January 29, 2013 stabilized by disulfide bonds, 19 whereas Ang1 (and COMP-Ang1) 20 forms higher-order multimers. The receptor-binding regions of VEGF and Ang1, which reside in the VEGF homology domain and fibrinogen-like domain, respectively, were fused in the same orientation with or without the Ang1 linker domain that accommodates the pericellular matrix-binding portion of Ang1 21 (constructs designated VA1 and VA2 in Figure 1A ). The proteins were produced in plasmid-transfected 293T cells and in Sf21 insect cells, and their receptor-binding properties were tested. Unlike native VEGF and Ang1, which bound only to their cognate receptors VEGFR-1/VEGFR-2 and Tie2, respectively, both VA polypeptides bound to all 3 receptors ( Figure 1B ). The binding affinity of VA1 to its cognate receptors was determined by the use of isothermal titration calorimetry ( Figure 1C ). Analysis of the VA1 protein by gel electrophoresis in reducing versus nonreducing conditions demonstrated that, similar to VEGF but unlike Ang1, the majority of the mature VA1 protein formed disulfide-bonded dimers, although a minor portion of the protein produced in mammalian 293T cells appeared as high-order multimers ( Figure 1D and Figure IA in the online-only Data Supplement). We next analyzed whether the VA1 protein can simultaneously bind to both VEGFR-2 and Tie2. Purified VEGFR-2-Fc protein, 22 bound to protein G Sepharose, was incubated with VA1-containing medium from transfected cells. After several washes, the beads were incubated with lysates of human umbilical vein endothelial cells that contain Tie2, washed again, and subjected to gel electrophoresis and Western blotting with Tie2-specific antibodies. The results indicated that VA1, unlike VEGF, Ang1, or control medium, is able to simultaneously bind to both receptors ( Figure 1E ). The receptor-binding properties of VA1 were also characterized in cultured human umbilical vein endothelial cells expressing a Tie2-green fluorescent protein fusion protein. 23 Ang1 treatment of these cells led to an accumulation of Tie2-green fluorescent protein in cell-cell junctions (arrows in Figure IB in the online-only Data Supplement and References 23 and 24). In similar conditions, VA1 (but not VEGF) produced in mammalian cells also led to Tie2 accumulation in cell-cell junctions, whereas the purified dimeric VA1 from insect cells gave less junctional Tie2-green fluorescent protein signal in this assay ( Figure IB in the online-only Data Supplement and data not shown).
Covalent cross-linking was used to further demonstrate the ability of VA1 to "bridge" VEGFR-2 and Tie2 in human primary endothelial cells. Blood vascular endothelial cells (BECs) were first serum starved and then treated with VA1, VEGF, or Ang1 for 20 minutes, followed by application of the cross-linking reagent for 30 minutes. The cells were lysed, and solubilized proteins were immunoprecipitated with anti-VEGFR-2 antibodies and Western blotted with anti-Tie2. VEGFR-2/Tie2 cross-linking was observed only in the presence of VA1 ( Figure 1F ).
We next studied whether the chimeric proteins could bind to and induce activation of VEGFRs in a cell-based assay. Mouse pro-B myelocytic leukemia cells BaF3, stably expressing human VEGFR-1/EpoR fusion receptor or VEGFR-2/ EpoR fusion receptor, were stimulated with serial dilutions of purified VA1 and VEGF proteins. Both VA1 and VEGF stimulated cell proliferation/survival in this assay, although the activity varied depending on the cell line used ( Figure 1G and H). Similar results were obtained with media from 293T cells expressing VA1 or VEGF (data not shown).
Receptor-Activating Properties of VA Chimeric Proteins
We next analyzed receptor-activating properties of the VA proteins in more detail. Similar to VEGF, both chimeric proteins activated VEGFR-2 phosphorylation in human umbilical vein endothelial cells and BECs (Figure 2A and 2B). Both chimeric proteins also stimulated Tie2 phosphorylation, although significantly less than Ang1, used as a positive control in this assay ( Figure 2A ). The reduced activity of the VA chimeras in the Tie2 phosphorylation assay resembled that of Ang2 ( Figure  IVA in the online-only Data Supplement and elsewhere 23, 25 ) , perhaps because of similar dimeric structures of the VA and Ang2 proteins, differentiating them from the multimeric structures of Ang1 and COMP-Ang1. 20 Because both VA forms behaved similarly in the above assays, only the linker-containing isoform VA1 was used in subsequent studies.
The above experiments demonstrated that although VA1 is able to bind to and activate VEGFR-2, it can simultaneously bind to (and weakly activate) Tie2, thus bridging the 2 receptors together. To address the question of how VA1 signals compared with VEGF, we first analyzed VEGFR-2 phosphorylation in cultured endothelial cells under continuous stimulation with the ligands for various periods of time. In these conditions, VA1 and VEGF were equally active in stimulating VEGFR-2 phosphorylation. Either treatment also resulted in transient phosphorylation of the mitogen-activated protein kinases Erk1 and Erk2 ( Figure IIA in the online-only Data Supplement).
Because continuous stimulation of the cells with high ligand concentrations did not reveal significant differences between VA1 and VEGF, we undertook an experimental setup in which BECs were stimulated with receptor-saturating amounts of VEGF or VA1 for 5 minutes, then extensively rinsed with temperature-and CO 2 -equilibrated serum-free medium, and further incubated for various periods of time in serum-free medium without the growth factors. Tyrosine phosphorylation of VEGFR-2 and Erk1/2 was then analyzed from the cell lysates by Western blotting. In these conditions, VEGF stimulated VEGFR-2 phosphorylation at Tyr1175 for a significantly longer time period than VA1 ( Figure 2B) . The difference was even more evident when the cells were stimulated with the mammalian cell-derived ligands and total phosphotyrosines of VEGFR-2 were determined ( Figure IIB in the online-only Data Supplement). As another control, we used a combined VEGF+Ang1 stimulation of BECs to find out whether the mere Tie2 activation was responsible for the differential VEGFR-2 phosphorylation. However, the addition of Ang1 did not affect VEGF-induced VEGFR-2 phosphorylation ( Figure IIB in the online-only Data Supplement). Compared with VEGF, VA1 treatment also resulted in less downregulation of the total VEGFR-2 protein in endothelial cells ( Figure 2B and Figure IIB in the online-only Data Supplement). Despite these differences, the duration of Erk1/2 phosphorylation differed only minimally between the cells stimulated with the 2 ligands, resembling the Erk1/2 phosphorylation response after continuous stimulation ( Figure IIA and IIB in the online-only Data Supplement).
To characterize downstream signaling events after endothelial cell stimulation with the ligands, we analyzed the phosphorylation of several secondary messengers such as p38, docking protein-2 (DokR), cAMP response element binding protein (CREB), and endothelial nitric oxide synthase. Compared with VEGF, VA1 induced a more transient increase in p38 and CREB phosphorylation, whereas DokR and endothelial nitric oxide synthase were equally phosphorylated after stimulation with both factors ( Figure IIC and IID in the online-only Data Supplement and data not shown).
The reduced ability of VA1 to stimulate VEGFR-2 degradation compared with VEGF prompted us to use 2 different approaches in which VEGFR-2 downregulation could be observed more directly. BECs were transduced with retroviruses encoding a VEGFR-2-cyan fluorescent protein fusion protein and stimulated with VA1, VEGF, or Ang1, and receptor internalization was analyzed 45 minutes later. The formation of VEGFR-2cyan fluorescent protein containing intracellular vesicles was strongly induced by VEGF but very weakly induced by VA1 or Ang1 ( Figure IIE in the online-only Data Supplement).
In another approach, we used BECs stimulated with VA1, VEGF, Ang1, or VEGF+Ang1 for 10 minutes. The incubation was then continued in fresh medium without growth factors for 30 minutes; cell-surface proteins were biotinylated; the cells were lysed; and biotinylated proteins were bound to streptavidin-agarose and subjected to Western blotting for VEGFR-2. As expected, VEGF led to downregulation of the VEGFR-2
Circulation
January 29, 2013 available for biotinylation on the cell surface because of receptor internalization, whereas VA1 or Ang1 treatment did not significantly alter cell-surface expression of VEGFR-2 ( Figure 2C ). We also analyzed whether VEGFR-2 was covalently modified by polyubiquitinylation for degradation in the proteasome after these treatments. BECs were stimulated for 10 minutes, lysed, and VEGFR-2 immunoprecipitated. Western blotting with anti-ubiquitin antibodies indicated that VEGF but not VA1 or angiopoietins induced polyubiquitinylation of VEGFR-2 ( Figure 2D ). The proteasome inhibitor MG132 was used in this experiment to prevent VEGFR-2 degradation to increase the sensitivity of the assay. In similar conditions, Tie2 was not ubiquitinylated ( Figure 2E ).
It has been demonstrated that VEGF is able to induce Tie2 ectodomain shedding, thus modulating Tie2 signaling. 26 VEGF has also been shown to stimulate Tie1 ectodomain shedding. 27 To analyze whether VA1 stimulates the ectodomain cleavages, BECs were stimulated with VA1, VEGF, Ang1, or VEGF+Ang1 (or phorbol-12-myristate-13-acetate (PMA) as a strong positive control), 26 and biotinylated BEC cell-surface proteins were analyzed by Western blotting for Tie2 and Tie1. VEGF alone or in combination with Ang1 led to Tie2 cleavage, releasing a 75-kDa fragment recognized by the anti-Tie2 antibodies (arrowhead in Figure 2F ). In contrast, VA1 or Ang1 did not affect Tie2 expression or cleavage. Ang2 treatment was similarly inactive in the ectodomain cleavage assay (data not shown). VEGF (but not VA1, Ang1, or Ang2) also led to a small decrease in the amount of the intact cell-surface Tie1 receptor ( Figure 2F and data not shown).
We next analyzed whether VE-cadherin phosphorylation and internalization differ between cells treated with VA1 and VEGF because VE-cadherin constitutes one of the key mechanisms maintaining vascular integrity in blood vessels. 28 Human umbilical vein endothelial cells were treated with VA1, VEGF, Ang1, Ang2, or BSA, and VE-cadherin Tyr658 phosphorylation was determined. VEGF increased the phosphorylation slightly, whereas VA1 or the VEGF+Ang1 combination induced strong VE-cadherin phosphorylation (P<0.05; Figure 3A and Figure III in the online-only Data Supplement). Strikingly, unlike VEGF, VA1 or the VEGF+Ang1 combination restored the initial downregulation of cellsurface VE-cadherin at the 30-minute time point ( Figure 3B ). Consistent with this, Src phosphorylation, which is involved in VEGF/VEGFR2-stimulated VE-cadherin phosphorylation and internalization, 29 was strongly increased by VEGF but was increased very little by VA1 or VEGF+Ang1 ( Figure 3C and Figure IIIB in the online-only Data Supplement).
VA1 Induces Angiogenesis With a Distinct Vessel Pattern in Skeletal Muscle and Skin
Because VA1 was able to stimulate VEGFR-2 and downstream kinases (such as extracellular signal-regulated kinase [Erk]-1/2) but showed differences in VEGFR-2 activation and downregulation kinetics, we wanted to analyze the angiogenic activity of VA1 versus VEGF in vivo. rAAVs encoding VA1, VEGF, Ang1, or the control protein (human serum albumin) were injected into tibialis anterior muscles of FVB/N mice at the dose of 8×10 9 vector genomes per muscle. The muscle Receptor activation and downstream signaling by VA1. A, Human umbilical vein endothelial cells were stimulated with the indicated ligands produced in 293T cells for 10 minutes and lysed, and vascular endothelial growth factor (VEGF) receptor (VEGFR)-2 and Tie2 were analyzed by Western blotting for phosphotyrosine (P-Tyr), VEGFR-2, or Tie2. B, Phosphorylation of VEGFR-2 (Tyr1175) after stimulation of blood vascular endothelial cells (BECs) with purified VEGF or VA1 proteins produced in Sf21 insect cells for 5 minutes, rinsing, and further incubation in medium without ligands for the indicated periods of time. WB indicates Western blot. C, VA1 promotes less internalization of VEGFR-2 than VEGF (V). Serum-starved BECs were stimulated with the indicated factors for 10 minutes, rinsed, and further incubated for 30 minutes. Surface proteins were biotinylated, and VEGFR-2 was analyzed as described in Method. A indicates angiopoietin. D and E, VA1 induces less ubiquitinylation of VEGFR-2 than VEGF and no Tie2 ubiquitinylation. Serum-starved BECs were stimulated for 10 minutes; VEGFR-2 or Tie2 was immunoprecipitated; and ubiquitinylated receptor proteins were visualized by Western blotting. F, VA1 does not induce internalization of Tie2 or Tie1. The experiment was performed essentially as described in C, but surface Tie2 and Tie1 were analyzed instead. vasculature was analyzed at 1 to 4 weeks. Four days after the injections, transgene-encoded protein expression was confirmed by ELISA in the muscle. VEGF and VA1 concentrations were 0.79±0.3 and 1.64±0.2 ng/mg tissue, respectively, indicating similar molar concentrations. Quantification of VEGF and VA1 protein expression at the very late time point (5 weeks after injection) showed that the proteins were expressed continuously in the treated muscles at similar levels (data not shown). Antibody staining of frozen muscle sections for the endothelial marker platelet endothelial cell adhesion molecule-1 ( Figure 4A and 4B, 4 weeks; Figure VA in the online-only Data Supplement, quantification for 1-4 weeks) and Doppler ultrasound analysis of the rAAV-treated muscles ( Figure 4C and 4D) demonstrated that VA1 retained the angiogenic (P<0.01) and perfusion-increasing (P<0.05) activities of VEGF. However, fluorescent (DiI) staining of the vessels via cardiac perfusion revealed distinct vascular patterns in the muscles treated with VA1 versus VEGF ( Figure 4E ). Whereas VEGF induced an angioma-like pattern consisting of enlarged vessels concentrated in "glomeruloid tufts" (see also the work by Carmeliet 30 ), the VA1-induced vessels were more dilated and evenly distributed. Human serum albumin, used as a control, did not have any angiogenic effect in these conditions. Ang1 and Ang2 induced a minor increase in the platelet endothelial cell adhesion molecule-1-positive endothelial area, although Ang1 treatment did not increase perfusion ( Figure 4A -D and Figure IVB and IVC in the online-only Data Supplement).
To characterize further the maturation of the vessels induced by these treatments, we stained muscle sections for markers expressed by pericytes and smooth muscle cells (chondroitin sulfate proteoglycan NG2, platelet-derived growth factor receptor-β, and α-smooth muscle actin, respectively). Quantification of the stained areas indicated that pericyte/smooth muscle cell coverage of the induced vessels was comparable between the VA1 and VEGF groups ( Figure  4A and B and Figures VA, VIA, and VIB in the online-only Data Supplement). Interestingly, the blood capillaries induced by VA1 appeared more regular than those induced by VEGF. This finding corresponds to the vessel pattern observed by DiI staining (compare the VA1 and VEGF panels in Figure 4E and Figure VIA in the online-only Data Supplement).
Immunohistochemical analysis of blood vessels in mouse skin after the injection of recombinant rAAVs demonstrated increased sprout formation and branching in VA1-treated samples compared with the VEGF-treated samples. Furthermore, rAAV-VEGF-induced angioma-like formations were not observed with rAAV-VA1 ( Figure VII 
VA1 Induces Less Permeability in Skeletal Muscle
To characterize vessel permeability in the transfected muscles, the Miles assay was used. In this assay, VEGF induced significant extravasation of the Evans Blue dye from the vessels of FVB/N mice after 1, 2, or 3 weeks, whereas the vascular permeability in the VA1-transfected muscle was significantly (P<0.001) lower ( Figure 5A and B, Figure VD in the onlineonly Data Supplement, and data not shown). Doubling of the virus dose did not result in increased Evans Blue extravasation at 1 or 2 weeks; only a minor increase occurred at 3 weeks ( Figure 5B ). Ang1 expression led to decreased dye extravasation, as previously published, 15 and Ang2 had no effect (Figures IVD and VD in the online-only Data Supplement). Compared with VEGF, VA1 also induced less Evans Blue extravasation in an acute vessel permeability test in the skin (data not shown). Further analysis of the treated muscles demonstrated that VA1 induced significantly less leukocyte recruitment to the muscles than VEGF ( Figure VB and VC in the online-only Data Supplement and data not shown).
VA1 Improves Perfusion in a Mouse Hind-limb Ischemia Model
To test the ability of VA1 to promote vessel growth in ischemic tissue, we used the mouse hind-limb ischemia model, involving a ligation closure of the femoral artery. 31 When immunodeficient mice are used in this model, limb survival requires an angiogenic inducer, whereas in immunocompetent Balb/c mice, the operated limbs often survive without such treatment, perhaps because of better spontaneous collateral growth. Therefore, we selected immunodeficient mice for the experiment to get a clearer readout of the results. We found that rAAV-VEGF transduction of the muscle was not effective in protecting the limb from necrosis (perhaps because of induction of angioma formation), whereas rAAV-VA1 improved blood flow restoration and protected the operated limb from necrosis (P<0.001; Figure 5C and D). Continuous expression of a transgenic protein such as VEGF in the rAAV-transduced tissue can cause abnormally high local concentrations, resulting in tissue damage rather than healing. To avoid this limitation and to perform the experiment in a more clinically relevant fashion, hind-limb ischemia was induced in immunocompetent Balb/c mice as indicated above, but purified proteins instead of the rAAVs were delivered. Single injections of equimolar amounts of the indicated proteins were done after the surgery, and blood perfusion was measured after 3 and 7 days, as described in the expanded Methods and Materials section in the online-only Data Supplement. The results showed that even such short pulses of either VA1 or VEGF improve blood perfusion in the operated limbs (P<0.05), with a small trend for VA1 to provide better perfusion ( Figure 6A and B ).
VA1 and VEGF Show Distinct Signaling Properties In Vivo
Results from the hind-limb ischemia model using a single injection of the proteins suggested that the treatment would provide a relatively long-lasting signal to initiate capillary growth. To analyze the signaling properties of VA1 and VEGF proteins in mouse tissues, we injected equimolar amounts of the proteins to the blood circulation of FVB/N mice and analyzed their concentration kinetics in serum and in the lung and phosphorylation of VEGFR-2 (Y1175) and the downstream Akt (S473) kinase in the lung. Lung was chosen for analysis because it is a highly vascularized tissue that provides clear signals. The injected ligands were cleared rapidly from the blood circulation. However, VA1 was retained in the lungs at a higher level Figure 6C ). Analysis of the lung lysates indicated that VEGFR-2 was tyrosine phosphorylated in both experimental groups. Compared with VEGF, VA1 led to slower VEGFR-2 downregulation (Figure 6D ). Furthermore, VA1 (or the VEGF+Ang1 combination) stimulated phosphorylation of Akt more strongly than VEGF in the lung and in cultured BECs ( Figure 6E ).
Discussion
In this work, we describe the chimeric VEGF-Ang1 growth factor VA1, designed by combining the receptor-binding domains of VEGF and Ang1. We show that VA1 retains the angiogenic properties of VEGF but induces significantly fewer angiomalike structures, less vessel permeability, and less inflammation in mouse skeletal muscle. In ischemic skeletal muscle, VA1, delivered via rAAVs, showed clear benefits over VEGF in restoring blood flow and rescuing the limb from necrosis. The angiogenic activity of VEGF is known to be mediated mainly via the activation of VEGFR-2. 6 In fact, ligands activating only VEGFR-2 such as VEGF-E and one of the VEGF-D isoforms are able to induce an angiogenic response. 6, 12 In endothelial cell cultures, both VEGF and VA1 stimulated strong VEGFR-2 phosphorylation, but differences were found in the phosphorylation kinetics of VEGFR-2, the serine/threonine-specific protein kinase Akt, the Src tyrosine kinase, the mitogen-activated protein kinases Erk1/2, p38, and the CREB transcription factor after VEGF versus VA1 stimulation. After short-term stimulation followed by removal of the unbound ligand and further incubation, VEGF induced a more prolonged phosphorylation of VEGFR-2 than VA1. Compared with VA1, VEGF also induced more VEGFR-2 ubiquitinylation and faster VEGFR-2 degradation.
To gain mechanistic insight into the differential properties of VEGF and VA1, we used several biochemical and cellular assays. Binding studies confirmed that VA1 binds VEGFR-2, Tie-2, and VEGFR-1. The affinity of VA1 for VEGFR-2 was comparable to that of VEGF 22 and, for Tie2, similar to the Ang-1 fibrinogen-like domain. 32 Furthermore, unlike VEGF, VA1 could simultaneously bind to both VEGFR-2 and Tie2, being capable of establishing a molecular link between these 2 major endothelial growth factor receptors in trans or in cis. This result was confirmed in cross-linking experiments using cultured endothelial cells. Compared with VEGFR-2, Tie2 is known to be internalized slowly and to be involved in multimeric in trans complexes stabilizing endothelial cell-cell contacts. 23, 24 Thus, the bivalent ligand VA1, via binding to both VEGFR-2 and Tie2, could establish multimeric complexes in which VEGFR-2 internalization and subsequently ubiquitinylation are significantly delayed. This conclusion was substantiated by our cellular assays indicating that VA1 Figure 5 . VA1 induces less vascular permeability but more vascular perfusion in ischemic hind limb than vascular endothelia growth factor (VEGF) when delivered via recombinant adeno-associated viral (rAAV). A, Representative images of Evans Blue staining in tibialis anterior muscles treated with the indicated rAAVs for 2 weeks. Ang1 indicates angiopoietin-1; and HSA, human serum albumin. B, Quantification of data from the Miles permeability assay 2 and 3 weeks after rAAV transduction. Two virus doses were tested (low, -8×10 9 viral particles; high, -1.34×10 10 viral particles) in 30 µL per muscle. ANOVA followed by the Tukey post hoc test was used. C, Tissue perfusion and ratio of necrosis in ischemic hind limbs treated with the indicated rAAVs. The regional tissue perfusion rate (%/min) was defined as the fraction of blood exchanged per minute in the vascular volume by time-series analysis of indocyanine green dye. Blood perfusion rate in the hind limb was measured at postoperative days (PODs) 0 and 7. The representative perfusion rate map and pseudo-scale bar are indicated in log scale. D, Correlation between regional perfusion rates of the ischemic hind limbs at POD 0 and limb necrosis levels at POD 7. The x axis shows the regional perfusion rate of the ischemic hind limbs (poor perfusion rate, 0%/min-30%/min; moderate perfusion rate, 30%/ min-80%/min). Normal hind limbs typically demonstrate a perfusion rate >500%/min. Shown are the best and the worst cases in each experimental group. promoted very little accumulation of VEGFR-2-containing intracellular vesicles. In contrast, in the same assays, VEGF potently stimulated VEGFR-2 internalization and directed the receptor to proteasomal degradation. Unlike VEGF, VA1 did not induce Tie2 (or Tie1) cleavage in cultured endothelial cells, thus stabilizing heterotrimeric ligand-receptor complexes on the cell surface. This was also reflected in the long half-life of VA1 in the lung vasculature. Short-time stimulation experiments indicated that VA1 versus VEGF treatment of endothelial cells results in distinct VEGFR-2 phosphorylation and internalization kinetics. The slow internalization and quick dephosphorylation of VEGFR-2 after short-time stimulation with VA1 suggest that it is dephosphorylated and inactivated by junctional phosphatases such as density-enhanced phosphatase-1. 33 Vascular endothelial protein tyrosine phosphatase, which becomes associated with Tie2 and VE-cadherin, 34 could also be involved in VEGFR-2 dephosphorylation. It is known that internalized VEGFR-2 remains in the endosomal compartments (sorting endosomes) 35 for some time, retaining its full activity. 36, 37 This was reflected in our assays on the biochemistry and internalization of VEGFR-2-cyan fluorescent protein. VEGFR-2-induced phosphorylation and disassembly of VE-cadherin of the adherens junctions is considered to be one of the key mechanisms of the VEGF-induced permeability response. 36, 38 VEGFR-2 can associate with VE-cadherin and, on VEGF stimulation, induce its phosphorylation, 39 in part via an Src-Vav2-PAKdependent mechanism. 28 In our experiments, we observed that VA1 induced VE-cadherin phosphorylation; however, this was not accompanied by its internalization, unlike with VEGF.
Stimulation of Tie2 by Ang1 was shown to counteract VEGF/VEGFR-2-mediated signaling and to maintain vascular integrity. 15, 40 Importantly, Ang1 can reduce plasma leakage and strengthen adult vasculature integrity even in the absence of mural cells. 41 Ang1 can inhibit VEGF-induced activation of Src, thus inhibiting VE-cadherin internalization and rescuing the endothelial barrier function. 29 Consistent with the above results, less Src phosphorylation was detected after VA1 treatment than after VEGF treatment. Although VA1 is a less potent stimulator of Tie2 phosphorylation than Ang1, Tie2 phosphorylation by VA1 could contribute to the improved permeability properties of VA1 compared with VEGF. Furthermore, VEGF sustained CREB phosphorylation for a significantly longer time than VA1. Because this phosphorylation correlates with reduced VE-cadherin cell-surface expression and increased endothelial monolayer permeability response, 42 it is also possible that VEGF downregulates VE-cadherin expression more than VA1.
Unlike VEGF, VA1 did not induce Tie2 or Tie1 ectodomain cleavage, thus providing an additional mechanism for the stabilization of heterotrimeric molecular complexes on endothelial cells. Furthermore, because leukocyte extravasation can occur through endothelial gaps 43 and Ang1 can decrease plasma leakage by reducing the number and size of endothelial gaps, 44 the reduced vessel leakiness associated with VA1 could also result in decreased accumulation of inflammatory cells in the treated muscles. We used 2 different hind-limb ischemia models employing femoral artery ligation to compare the therapeutic abilities of VA1 and VEGF to restore blood flow and to rescue the ischemic hind limb. The results showed a clear benefit of VA1 over VEGF when the therapeutic agents were delivered into the ischemic limb via rAAV. In the second model, using single injection of purified therapeutic proteins after the surgery, VA1 and VEGF were comparable in restoring blood perfusion, although VA1 showed a trend toward better performance. We could furthermore show that VA1 is retained in highly vascularized tissues better than VEGF and that it stimulates the antiapoptotic protein kinase Akt more efficiently than VEGF both in vitro and in vivo.
Reports published over the past decade have shown that the effect of VEGF in ischemic limb depends on its dose in the transduced muscle tissue, on the mouse strain, and on the delivery method. [45] [46] [47] [48] It was shown that lower or transient VEGF expression results in the formation of unstable vessels poorly covered by pericytes that are prone to regression. 49 On the contrary, higher and sustained VEGF expression can lead to angioma growth and poor perfusion, thus posing the challenge of finding an appropriate VEGF dose. 47, 50 The failure to obtain optimal VEGF expression could be a possible reason for the lack of a therapeutic effect when VEGF was delivered via rAAVs in the present study. On the other hand, an excess of VA1 may not be equally harmful because it induces less vascular leakage and inflammation, thus providing more flexibility for its practical use.
Conclusions
We have designed and characterized a chimeric molecule, VA1, that is strongly angiogenic in skeletal muscle but does not induce angioma-like growth, vascular permeability, or inflammatory cell recruitment to the same degree as VEGF. VA1 was found to be very effective in restoring blood flow and rescuing ischemic muscle in the mouse hind-limb model. These properties make VA1 an attractive alternative for proangiogenic gene therapy.
SUPPLEMENTAL MATERIAL
Expanded Methods
Construction and production of the rAAV vectors.
The rAAV encoding VEGF165 was published previously. 1 
VE-cadherin phosphorylation/internalization and Src phosphorylation assays.
To measure VE-cadherin tyrosine phosphorylation, HUVECs were grown to confluence, serum-starved and stimulated with the indicated proteins (500 ng/ml of each) for 5 min. The cells were then fixed and permeabilized with 3% paraformaldehyde (PFA), 0.5% Triton-X100 (Tx) in PBS for 3 min followed by further 15 min fixation with 3% PFA in PBS. Affinity purified rabbit antibody to VEcadherin P-Tyr658 peptide was produced and purified by New England Peptide.
Antibody ( VE-cadherin internalization assay was performed as previously described. 6 Briefly, to measure internalization of endogenous VE-cadherin, HUVECs were treated with chloroquine 300 µM for 3 h. Cells were incubated with mouse monoclonal BV-6 antibody (mAb) directed against the VE-cadherin extracellular domain (Millipore, Billerica, MA) for 1 h at 4oC in MCDB131 buffer, supplemented with 1% BSA medium. Cells were then rinsed with ice-cold MCDB131 to remove unbound antibody and treated with the indicated proteins (500 ng/ml of each) for 5 or 30 min.
The cells were then lysed and surface VE-cadherin was immunoprecipitated, followed by western blotting for VE-cadherin with the same mouse monoclonal BV-6 antibody.
Src (Tyr416) phosphorylation was determined by western blotting in total cell lysates of HUVECs, cultured and stimulated as described above for VE-cadherin internalization studies, using rabbit monoclonal anti-phospho-Src (Tyr416) antibody (Cell Signaling Technology Inc., Danvers, MA). Total Src was determined using rabbit monoclonal anti-Src antibody (Cell Signaling Technology Inc.). In this experiment, HRP-generated chemiluminescence was acquired and recorded using the Chemidoc system (Bio-Rad).
MTT cell survival assay and analysis of protein expression by IP.
For analysis of protein expression, supernatants containing the growth factors of interest were produced by rAAV vector transfection of 293T cells using the jetPEI transfection reagent (Polyplus-transfection). Proteins were metabolically labeled with 
Cross-linking experiments.
BECs were starved for 3 h, treated with the indicated proteins for 20 min, and then with DTSSP (3,3'-Dithiobis(sulfosuccinimidyl propionate)) for 30 min. The cells were lysed, solubilized proteins were immunoprecipitated with anti-VEGFR-2 antibodies and Western-blotted with anti-Tie2.
Tissue transduction with the rAAV vectors.
For transduction of the ear skin, six to seven week-old female C57BL/6 mice were anesthetized with xylazine and ketamine and 5 x 10 9 rAAV particles (in 10 µl volume)
were injected into each ear. One week after the injections the mice were perfusionfixed, and the ears were harvested, PFA-fixed and whole-mount stained.
Quantification of protein expression in transduced skeletal muscle.
rAAV-transduced muscles were weighed and homogenized in 0.2% Triton X-100 in PBS supplemented with protease inhibitors, using PowerLyzer TM muscles of anesthetized mice two weeks post-transduction. Image stacks were generated by three-dimensional scanning, and percent vascularity in the muscle mid region was analyzed using the VEVO 700 analysis software (VisualSonics).
Mouse hindlimb ischemia model with rAAV delivery.
CAnN.Cg-Foxn1 nu/CrljOri nude male mice were obtained from Orient Bio, Korea.
All mice were 6-12 weeks ( 
